Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498867 | 0.92 | KMT2A (0.53) | KMT2AMEN1CAPN1ERAP1MCL1 | |
| SCHEMBL3498868 | 0.92 | KMT2A (0.53) | KMT2AMEN1CAPN1ERAP1MCL1 | |
| SCHEMBL3504496 | 0.86 | CAPN1 (0.49) | KMT2AMEN1CAPN1 | |
| SCHEMBL3504494 | 0.86 | CAPN1 (0.49) | KMT2AMEN1CAPN1 | |
| SCHEMBL3498196 | 0.84 | GPR34 (0.63) | KMT2AMEN1MMP2GPR34 | |
| SCHEMBL3499991 | 0.84 | GPR34 (0.63) | KMT2AMEN1MMP2GPR34 | |
| SCHEMBL13344477 | 0.84 | GPR34 (0.63) | KMT2AMEN1MMP2GPR34 | |
| SCHEMBL3499197 | 0.81 | PPARA (0.44) | KMT2AMEN1CAPN1ERAP1MCL1 | |
| SCHEMBL3498243 | 0.81 | SHMT1 (0.40) | KMT2AMEN1MCL1ADAMTS5MMP2 | |
| SCHEMBL3498156 | 0.80 | MCL1 (0.49) | KMT2AMEN1MCL1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NAALAD2 1380/4885FOLH1 1311/4885KMT2A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.